All In Biotech

Free tool

FAERS Monitor: Edarbyclor

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 202331 or its brand name (Edarbyclor, Azilsartan Kamedoxomil, Chlorthalidone). Reports on generic versions are filed under their own applications.

Reports

1,259

Serious

648

51% of reports

Hospitalization

222

Death reported

39

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness108
  • fatigue78
  • blood pressure increased72
  • drug ineffective67
  • diarrhoea62
  • nausea62
  • hypotension58
  • hypertension56
  • headache55
  • asthenia49
  • hyponatraemia47
  • dyspnoea44
  • muscle spasms44
  • pain39
  • pneumonia38

Reports by year received

View as table
YearReports
201233
201331
201446
201568
2016189
2017144
2018131
2019133
2020119
202176
202253
202380
202462
202560
202634

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,900 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyponatraemiaSignal4714.010.5553
blood pressure increasedSignal727.96.3428
hypotensionSignal584.83.8174
hypertensionSignal564.43.4146
muscle spasmsSignal444.03.097
dizzinessSignal1083.63.0207
astheniaSignal492.21.731
pneumonia382.01.417
fatigue781.71.421
diarrhoea621.61.314
headache551.51.18
nausea621.31.04
dyspnoea441.31.03
pain391.10.80
drug ineffective670.80.72

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.